Identification

Name
Naproxen
Accession Number
DB00788  (APRD01135, DB08298)
Type
Small Molecule
Groups
Approved, Vet approved
Description

An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.

Structure
Thumb
Synonyms
  • (+)-(S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid
  • (+)-(S)-Naproxen
  • (+)-2-(6-Methoxy-2-naphthyl)propionic acid
  • (+)-2-(Methoxy-2-naphthyl)-propionic acid
  • (+)-2-(Methoxy-2-naphthyl)-propionsäure
  • (+)-Naproxen
  • (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid
  • (S)-(+)-Naproxen
  • (S)-2-(6-Methoxy-2-naphthyl)propanoic acid
  • (S)-2-(6-Methoxy-2-naphthyl)propionic acid
  • (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
  • (S)-Naproxen
  • Naprolag
  • Naproxen
  • Naproxène
  • Naproxeno
  • Naproxenum
External IDs
RS 3540 / RS 3650 / RS-3540
Product Ingredients
IngredientUNIICASInChI Key
Naproxen sodium9TN87S3A3C26159-34-2CDBRNDSHEYLDJV-FVGYRXGTSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AnaproxTablet275 mgOralSyntex Inc.1980-12-311996-09-30Canada
AnaproxTablet275 mgOralAtnahs Pharma Uk Limited1995-12-31Not applicableCanada
AnaproxTablet275 mg/1OralGenentech, Inc.1980-09-042017-01-31Us
Anaprox DSTablet550 mgOralAtnahs Pharma Uk Limited1995-12-31Not applicableCanada
Anaprox DSTablet550 mg/1OralCanton Laboratories2016-06-01Not applicableUs
Anaprox DSTablet550 mg/1OralGenentech, Inc.1980-09-042018-07-31Us
Anaprox DS Tab 550mgTablet550 mgOralSyntex Inc.1990-12-311996-09-30Canada
Apo Naproxen Tab 125mgTablet125 mgOralApotex Corporation1982-12-31Not applicableCanada
EC-NaprosynTablet, delayed release500 mg/1OralGenentech, Inc.1994-10-142018-07-31Us
EC-NaprosynTablet, delayed release375 mg/1OralCanton Laboratories2016-06-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
All Day ReliefTablet220 mg/1OralRemedy Repack2015-03-092017-03-14Us
AnaproxTablet550 mg/1OralDirectrx2016-07-11Not applicableUs
Apo-napro-NATablet275 mgOralApotex Corporation1989-12-31Not applicableCanada
Apo-napro-NA DSTablet550 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-naproxenTablet500 mgOralApotex Corporation1983-12-31Not applicableCanada
Apo-naproxenTablet250 mgOralApotex Corporation1982-12-31Not applicableCanada
Apo-naproxenTablet375 mgOralApotex Corporation1983-12-31Not applicableCanada
Apo-naproxen ECTablet, delayed release375 mgOralApotex Corporation2003-04-23Not applicableCanada
Apo-naproxen ECTablet, delayed release500 mgOralApotex Corporation2003-04-23Not applicableCanada
Apo-naproxen EC TabletsTablet, delayed release250 mgOralApotex Corporation2003-04-23Not applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Naproxen SodiumTablet, film coated220 mg/1Oral7 Eleven2014-08-052017-11-22Us
7 Select Naproxen SodiumTablet, film coated220 mg/1Oral7 Eleven2014-08-11Not applicableUs
AleveTablet220 mg/1OralNavajo Manuracturing Company2016-09-17Not applicableUs
AleveTablet220 mg/1OralR J General Corporation2014-02-26Not applicableUs
AleveTablet220 mg/1OralLil' Drug Store Products, Inc.2000-01-01Not applicableUs
AleveTablet220 mgOralBayer2009-06-15Not applicableCanada
AleveCapsule, liquid filled220 mg/1OralBayer Health Care Llc.2007-02-20Not applicableUs
AleveTablet220 mg/1OralCardinal Health1994-01-112018-05-18Us
AleveTablet220 mg/1OralBayer Health Care Llc.2002-07-26Not applicableUs
Aleve Back and Body PainCapsule220 mgOralBayer2015-06-30Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aleve NighttimeNaproxen sodium (220 mg) + Diphenhydramine hydrochloride (25 mg)TabletOralBayer2016-02-24Not applicableCanada
Aleve PMNaproxen sodium (220 mg/1) + Diphenhydramine hydrochloride (25 mg/1)Tablet, film coatedOralBayer Health Care Llc.2014-09-09Not applicableUs
Aleve-D Sinus and ColdNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)TabletOralBayer Health Care Llc.2014-01-01Not applicableUs
Aleve-D Sinus and HeadacheNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)TabletOralBayer Health Care Llc.2014-01-01Not applicableUs
All Day Sinus and Cold DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralWalgreen2013-05-23Not applicableUs
All Day Sinus and Cold DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralHyvee2013-08-12Not applicableUs
Flanax Pain Relief KitNaproxen + Capsicum oleoresin + Menthol + Methyl salicylateKitBelmora LLC2015-08-252017-08-08Us
Good Neighbor Pharmacy Sinus and Cold DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralAmerisource Bergen2013-08-22Not applicableUs
Health Mart Sinus and Cold DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralMc Kesson2013-08-15Not applicableUs
Leader Sinus and Cold DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralCardinal Health2017-06-07Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Equipto - Naproxen External Cream Compounding KitNaproxenKitTopicalAlvix Laboratories2015-01-202018-03-14Us
TheraproxenNaproxen + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-05-192016-10-13Us
Theraproxen-500Naproxen + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-03-032016-10-13Us
Theraproxen-90Naproxen + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-052016-10-13Us
International/Other Brands
Alidase (Laboratorios) / Alpoxen (Actavis) / Alpron (Aldril) / Apain (Marvic) / Apranax (Roche) / Apronax (Bayer) / Bonyl (Orion) / Bruproxen (Bruluart) / Bumaflex N (Nycomed) / Congex (Buxton) / Debril (Monserrat) / Deproxen (Drug International) / Dysmenalgit (Krewel Meuselbach) / Emox (Emo-Farm) / Emoxen (EMO) / Eurogesic (Saval) / Fabralgina (Fabra) / Feminax Ultra (Bayer) / Flogotone (Interpharma) / Gerinap (Gerard) / Honlow (Panion & BF) / Improstan (Farmacoop) / Inflamax (Farmaceutica) / Inza (Alphapharm) / Iraxen (Quilab) / Jinkangpuli (Conba) / Lexinax (Brisafarma) / Melgar (Hexa) / Messelxen (Biomep) / Mobilat (STADA) / Naprometin (Roche) / Naprosyn CR (Abdi Ibrahim) / Naprosyn EC (Roche) / Naprosyn Entero (Roche) / Naprosyn SR (Roche) / Naprosyne (Roche) / Naproval (Labinco) / Naprux (Andromaco) / Neuralprona (Lba) / Noflam (Mylan) / Nopain (Medicef) / Prexan (New Research) / Priaxen (Remedica) / Princeps (Laser ) / Pronaxen (Orion) / Proxen (Grünenthal) / Proxen S (Roche) / Proxen SR (Roche) / Releve (General Pharma) / Repro (Doctor's Chemical Works) / Reuxen (Helcor) / Riproxen (BioGenet) / Sanaprox (Perumed) / Seladin (YSP) / Servinaprox (Novartis) / Tarproxen (Polfa Tarchomin) / Ticoflex (Incepta) / Tundra (Frasca) / Xenar (Elder) / Xenar-CR (Elder)
Categories
UNII
57Y76R9ATQ
CAS number
22204-53-1
Weight
Average: 230.2592
Monoisotopic: 230.094294314
Chemical Formula
C14H14O3
InChI Key
CMWTZPSULFXXJA-VIFPVBQESA-N
InChI
InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
IUPAC Name
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
SMILES
COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O

Pharmacology

Indication

For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, and acute gout. Also for the relief of mild to moderate pain and the treatment of primary dysmenorrhea.

Associated Conditions
Pharmacodynamics

Naproxen is a member of the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Naproxen has analgesic and antipyretic properties. As with other NSAIDs, its mode of action is not fully understood; however, its ability to inhibit prostaglandin synthesis may be involved in the anti-inflammatory effect.

Mechanism of action

The mechanism of action of naproxen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity.

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
UPeptostreptococcal albumin-binding proteinNot AvailablePeptostreptococcus magnus
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo bioavailability of 95%. Although naproxen itself is well absorbed, the sodium salt form is more rapidly absorbed resulting in higher peak plasma levels for a given dose. Food causes a slight decrease in the rate absorption.

Volume of distribution
Not Available
Protein binding

At therapeutic levels naproxen is greater than 99% albumin-bound.

Metabolism

Naproxen is extensively metabolized to 6-0-desmethyl naproxen and both parent and metabolites do not induce metabolizing enzymes.

Route of elimination
Not Available
Half life

The observed terminal elimination half-life is approximately 15 hours.

Clearance
Not Available
Toxicity

ORAL (LD50): Acute: 248 mg/kg [Rat]. 360 mg/kg [Mouse]. Symptoms of overdose include drowsiness, heartburn, indigestion, nausea, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Naproxen Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinNaproxen may increase the anticoagulant activities of (R)-warfarin.Experimental
(S)-WarfarinNaproxen may increase the anticoagulant activities of (S)-Warfarin.Experimental, Investigational
4-hydroxycoumarinNaproxen may increase the anticoagulant activities of 4-hydroxycoumarin.Experimental
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Abciximab.Approved
AbirateroneThe serum concentration of Naproxen can be increased when it is combined with Abiraterone.Approved
AcebutololNaproxen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Naproxen is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Naproxen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolNaproxen may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Naproxen.Approved, Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Acetylsalicylic acid.Approved, Vet Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Naproxen.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Naproxen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of gastrointestinal irritation can be increased when Alclometasone is combined with Naproxen.Approved
AldosteroneThe risk or severity of gastrointestinal irritation can be increased when Aldosterone is combined with Naproxen.Experimental, Investigational
Alendronic acidThe risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Alendronic acid.Approved
AliskirenThe risk or severity of renal failure and hypertension can be increased when Naproxen is combined with Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Alminoprofen.Experimental
AlosetronThe metabolism of Naproxen can be decreased when combined with Alosetron.Approved, Withdrawn
AloxiprinThe therapeutic efficacy of Aloxiprin can be decreased when used in combination with Naproxen.Experimental
AlprenololNaproxen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Naproxen.Approved, Investigational
AlteplaseThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Alteplase.Approved
AmbrisentanThe therapeutic efficacy of Ambrisentan can be decreased when used in combination with Naproxen.Approved, Investigational
AmcinonideThe risk or severity of gastrointestinal irritation can be increased when Amcinonide is combined with Naproxen.Approved
AmediplaseThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Amediplase.Investigational
AmikacinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Amiloride.Approved
AminophenazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidThe therapeutic efficacy of Aminosalicylic Acid can be decreased when used in combination with Naproxen.Approved
AmiodaroneThe metabolism of Naproxen can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Naproxen.Approved
Amphotericin BThe risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Naproxen.Approved, Investigational
AnagrelideThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Anagrelide.Approved
AncrodThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Ancrod.Approved, Investigational
AnisodamineNaproxen may decrease the antihypertensive activities of Anisodamine.Investigational
AnistreplaseThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Naproxen is combined with Antipyrine.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Naproxen is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Naproxen can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe risk or severity of adverse effects can be increased when Naproxen is combined with Apixaban.Approved
ApramycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Apramycin.Experimental, Vet Approved
AprepitantThe metabolism of Naproxen can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Arbekacin.Approved, Investigational
ArdeparinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Argatroban.Approved, Investigational
ArotinololNaproxen may decrease the antihypertensive activities of Arotinolol.Investigational
AstaxanthinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Astaxanthin.Investigational
AtenololNaproxen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Naproxen.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Naproxen.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Naproxen is combined with Balsalazide.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Naproxen.Approved, Investigational
BefunololNaproxen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Bekanamycin.Experimental
BemiparinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Benazeprilat.Experimental
BendazacThe risk or severity of adverse effects can be increased when Naproxen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naproxen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Naproxen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Benoxaprofen.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Naproxen.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Naproxen is combined with Benzydamine.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Naproxen.Approved, Withdrawn
BeraprostThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Beraprost.Investigational
BesifloxacinNaproxen may increase the neuroexcitatory activities of Besifloxacin.Approved
BetamethasoneThe risk or severity of gastrointestinal irritation can be increased when Betamethasone is combined with Naproxen.Approved, Vet Approved
BetaxololNaproxen may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Naproxen.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Naproxen.Approved, Investigational
BevantololNaproxen may decrease the antihypertensive activities of Bevantolol.Approved
BietaserpineThe therapeutic efficacy of Bietaserpine can be decreased when used in combination with Naproxen.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Naproxen.Approved, Investigational
BisoprololNaproxen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Bivalirudin.Approved, Investigational
BopindololNaproxen may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Naproxen can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe therapeutic efficacy of Bosentan can be decreased when used in combination with Naproxen.Approved, Investigational
BQ-123The therapeutic efficacy of BQ-123 can be decreased when used in combination with Naproxen.Investigational
BretyliumThe therapeutic efficacy of Bretylium can be decreased when used in combination with Naproxen.Approved
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Naproxen.Approved
BrinaseThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Naproxen.Approved
BucindololNaproxen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Naproxen.Approved
BufexamacThe risk or severity of adverse effects can be increased when Naproxen is combined with Bufexamac.Approved, Experimental
BufuralolNaproxen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Naproxen.Approved
BupranololNaproxen may decrease the antihypertensive activities of Bupranolol.Approved
CadralazineThe therapeutic efficacy of Cadralazine can be decreased when used in combination with Naproxen.Experimental
CaffeineThe metabolism of Naproxen can be decreased when combined with Caffeine.Approved
CandesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Naproxen.Experimental
Candesartan cilexetilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan cilexetil is combined with Naproxen.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Naproxen.Experimental
CangrelorThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Cangrelor.Approved
CapecitabineThe metabolism of Naproxen can be decreased when combined with Capecitabine.Approved, Investigational
CapreomycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Capreomycin.Approved
CaptoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Captopril.Approved
CarbamazepineThe serum concentration of Naproxen can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Naproxen is combined with Carbaspirin calcium.Experimental, Investigational
CarboplatinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Carboplatin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Naproxen.Approved
CarbutamideThe protein binding of Carbutamide can be decreased when combined with Naproxen.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololNaproxen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNaproxen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CefacetrileThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefacetrile.Approved
CefaclorThe risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Naproxen.Approved
CefadroxilThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Naproxen.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefapirin.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefatrizine.Experimental
CefazedoneThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefazedone.Experimental
CefazolinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefazolin.Approved
CefbuperazoneThe risk or severity of nephrotoxicity can be increased when Cefbuperazone is combined with Naproxen.Experimental
CefcapeneThe risk or severity of nephrotoxicity can be increased when Cefcapene is combined with Naproxen.Experimental
CefditorenThe risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Naproxen.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity can be increased when Cefepime is combined with Naproxen.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity can be increased when Cefetamet is combined with Naproxen.Experimental
CefmenoximeThe risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Naproxen.Approved
CefmetazoleThe risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Naproxen.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Naproxen.Approved
CefodizimeThe risk or severity of nephrotoxicity can be increased when Cefodizime is combined with Naproxen.Experimental
CefonicidThe risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Naproxen.Approved, Investigational
CefoperazoneThe risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Naproxen.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Naproxen.Approved
CefotaximeThe risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Naproxen.Approved
CefotetanThe risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Naproxen.Approved
CefotiamThe risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Naproxen.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Naproxen.Approved
CefozopranThe risk or severity of nephrotoxicity can be increased when Cefozopran is combined with Naproxen.Experimental
CefpiramideThe risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Naproxen.Approved
CefpiromeThe risk or severity of nephrotoxicity can be increased when Cefpirome is combined with Naproxen.Approved
CefpodoximeThe risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Naproxen.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Naproxen.Approved
CefradineThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefradine.Approved
CefroxadineThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefroxadine.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity can be increased when Cefsulodin is combined with Naproxen.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Ceftaroline fosamil.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Naproxen.Approved
CeftezoleThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Ceftezole.Experimental
CeftibutenThe risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Naproxen.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Naproxen.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Ceftobiprole.Approved, Investigational
CeftriaxoneThe risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Naproxen.Approved
CefuroximeThe risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Naproxen.Approved
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Naproxen.Approved, Investigational
CeliprololNaproxen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cephaloglycin.Approved
CephaloridineThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cephaloridine.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cephalothin Group.Experimental
CeritinibThe serum concentration of Naproxen can be increased when it is combined with Ceritinib.Approved
CertoparinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Certoparin.Approved, Investigational
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
ChlorpropamideThe protein binding of Chlorpropamide can be decreased when combined with Naproxen.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Naproxen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Naproxen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of gastrointestinal irritation can be increased when Ciclesonide is combined with Naproxen.Approved, Investigational
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Naproxen.Investigational
CilazaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Naproxen is combined with Cimicoxib.Investigational
CinoxacinNaproxen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe metabolism of Naproxen can be decreased when combined with Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Naproxen.Approved
CitalopramCitalopram may increase the antiplatelet activities of Naproxen.Approved
ClobetasolThe risk or severity of gastrointestinal irritation can be increased when Clobetasol is combined with Naproxen.Approved, Investigational
Clobetasol propionateThe risk or severity of gastrointestinal irritation can be increased when Clobetasol propionate is combined with Naproxen.Approved
ClobetasoneThe risk or severity of gastrointestinal irritation can be increased when Clobetasone is combined with Naproxen.Approved
ClocortoloneThe risk or severity of gastrointestinal irritation can be increased when Clocortolone is combined with Naproxen.Approved
Clodronic AcidThe risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Naproxen.Approved
ClonixinThe risk or severity of adverse effects can be increased when Naproxen is combined with Clonixin.Approved
CloprednolThe risk or severity of gastrointestinal irritation can be increased when Cloprednol is combined with Naproxen.Experimental
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Naproxen.Vet Approved
CloranololNaproxen may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneNaproxen may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Naproxen can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColistimethateThe risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Naproxen.Approved, Vet Approved
CorticotropinThe risk or severity of gastrointestinal irritation can be increased when Corticotropin is combined with Naproxen.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Cortisone acetate is combined with Naproxen.Approved, Investigational
CortivazolThe risk or severity of gastrointestinal irritation can be increased when Cortivazol is combined with Naproxen.Investigational
CrisaboroleThe metabolism of Naproxen can be decreased when combined with Crisaborole.Approved, Investigational
CryptenamineThe therapeutic efficacy of Cryptenamine can be decreased when used in combination with Naproxen.Approved
CurcuminThe metabolism of Naproxen can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Naproxen.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Naproxen is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Naproxen.Approved
Cyproterone acetateThe serum concentration of Naproxen can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Naproxen can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Dalteparin.Approved
DanaparoidThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Naproxen.Investigational
DarexabanThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Darexaban.Investigational
DebrisoquinThe therapeutic efficacy of Debrisoquin can be decreased when used in combination with Naproxen.Approved, Investigational
DeferasiroxThe risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Naproxen is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of gastrointestinal irritation can be increased when Deflazacort is combined with Naproxen.Approved, Investigational
DelaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Delapril.Investigational
DelavirdineThe metabolism of Naproxen can be decreased when combined with Delavirdine.Approved
DersalazineThe therapeutic efficacy of Dersalazine can be decreased when used in combination with Naproxen.Investigational
DeserpidineThe therapeutic efficacy of Deserpidine can be decreased when used in combination with Naproxen.Approved
DesirudinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Desirudin.Approved
DesmopressinThe risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Naproxen is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Desmoteplase.Investigational
DesonideThe risk or severity of gastrointestinal irritation can be increased when Desonide is combined with Naproxen.Approved, Investigational
DesoximetasoneThe risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Naproxen.Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Naproxen.Approved, Investigational
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Naproxen.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone isonicotinate is combined with Naproxen.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Dexketoprofen.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Naproxen.Experimental
DextranThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Dextran.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Diazoxide can be decreased when used in combination with Naproxen.Approved
DibekacinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Dibekacin.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Naproxen.Approved, Vet Approved
DicoumarolNaproxen may increase the anticoagulant activities of Dicoumarol.Approved
DiethylnorspermineThe therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Naproxen.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Naproxen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of gastrointestinal irritation can be increased when Diflorasone is combined with Naproxen.Approved
DifloxacinNaproxen may increase the neuroexcitatory activities of Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Naproxen is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Naproxen.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of gastrointestinal irritation can be increased when Difluprednate is combined with Naproxen.Approved
DigoxinNaproxen may decrease the excretion rate of Digoxin which could result in a higher serum level.Approved
DihydralazineThe therapeutic efficacy of Dihydralazine can be decreased when used in combination with Naproxen.Approved, Investigational
DihydrostreptomycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Naproxen.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Naproxen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Naproxen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Naproxen.Approved
DiphenadioneNaproxen may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Dipyridamole.Approved
DitazoleThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Ditazole.Approved, Withdrawn
DorzolamideThe therapeutic efficacy of Dorzolamide can be decreased when used in combination with Naproxen.Approved
DosulepinThe metabolism of Naproxen can be decreased when combined with Dosulepin.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Naproxen.Approved
DrospirenoneThe risk or severity of hyperkalemia can be increased when Naproxen is combined with Drospirenone.Approved
Drotrecogin alfaThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Naproxen is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Naproxen.Approved
Edetic AcidThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Naproxen can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Naproxen.Approved, Investigational
EnalaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Enalaprilat.Approved
EndralazineThe therapeutic efficacy of Endralazine can be decreased when used in combination with Naproxen.Experimental
EnoxacinThe metabolism of Naproxen can be decreased when combined with Enoxacin.Approved, Investigational
EnoxaparinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Naproxen.Experimental
EpanololNaproxen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Naproxen is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Naproxen.Experimental
EplerenoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Naproxen.Approved
EprosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Naproxen.Approved
EsatenololNaproxen may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Naproxen.Approved, Investigational
EsmololNaproxen may decrease the antihypertensive activities of Esmolol.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naproxen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Naproxen is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Naproxen can be decreased when it is combined with Ethinyl Estradiol.Approved
Ethyl biscoumacetateNaproxen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Naproxen.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Naproxen is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Naproxen is combined with Etoricoxib.Approved, Investigational
FelbamateThe metabolism of Naproxen can be decreased when combined with Felbamate.Approved
FelbinacThe risk or severity of adverse effects can be increased when Naproxen is combined with Felbinac.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Naproxen.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fenbufen.Approved
FenoldopamThe therapeutic efficacy of Fenoldopam can be decreased when used in combination with Naproxen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Naproxen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Naproxen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Naproxen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Naproxen.Experimental
FibrinolysinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Naproxen.Approved, Investigational
FirocoxibThe risk or severity of adverse effects can be increased when Naproxen is combined with Firocoxib.Experimental, Vet Approved
FleroxacinNaproxen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Naproxen is combined with Floctafenine.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity can be increased when Flomoxef is combined with Naproxen.Investigational
FloxuridineThe metabolism of Naproxen can be decreased when combined with Floxuridine.Approved
FlucloroloneThe risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Naproxen.Experimental
FluconazoleThe metabolism of Naproxen can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Fludrocortisone is combined with Naproxen.Approved, Investigational
FluindioneNaproxen may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineNaproxen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of gastrointestinal irritation can be increased when Flumethasone is combined with Naproxen.Approved, Vet Approved
FlunisolideThe risk or severity of gastrointestinal irritation can be increased when Flunisolide is combined with Naproxen.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Naproxen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of gastrointestinal irritation can be increased when Fluocinolone Acetonide is combined with Naproxen.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of gastrointestinal irritation can be increased when Fluocinonide is combined with Naproxen.Approved, Investigational
FluocortinThe risk or severity of gastrointestinal irritation can be increased when Fluocortin is combined with Naproxen.Experimental
FluocortoloneThe risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Naproxen.Approved, Withdrawn
FluorometholoneThe risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Naproxen.Approved, Investigational
FluorouracilThe metabolism of Naproxen can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Naproxen.Approved, Vet Approved
FluperoloneThe risk or severity of gastrointestinal irritation can be increased when Fluperolone is combined with Naproxen.Experimental
FluprednideneThe risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Naproxen.Approved, Withdrawn
FluprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Fluprednisolone is combined with Naproxen.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Naproxen.Vet Approved
FlurandrenolideThe risk or severity of gastrointestinal irritation can be increased when Flurandrenolide is combined with Naproxen.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Naproxen.Approved, Investigational
FluticasoneThe risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Naproxen.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone furoate is combined with Naproxen.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Naproxen.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Naproxen.Approved, Investigational
FondaparinuxThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Fondaparinux.Approved, Investigational
ForasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Naproxen.Experimental
FormocortalThe risk or severity of gastrointestinal irritation can be increased when Formocortal is combined with Naproxen.Experimental
FoscarnetThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Foscarnet.Approved
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Fosinoprilat.Experimental
FosphenytoinThe metabolism of Naproxen can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Framycetin.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Naproxen.Approved, Vet Approved
GabexateThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Gabexate.Investigational
GarenoxacinNaproxen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNaproxen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Naproxen.Approved, Withdrawn
GemfibrozilThe metabolism of Naproxen can be decreased when combined with Gemfibrozil.Approved
GemifloxacinNaproxen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Geneticin.Experimental
GentamicinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with GENTAMICIN C1A.Experimental
GliclazideThe protein binding of Gliclazide can be decreased when combined with Naproxen.Approved
GlipizideThe protein binding of Glipizide can be decreased when combined with Naproxen.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Naproxen.Approved
GrepafloxacinNaproxen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Naproxen is combined with Guacetisal.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Naproxen.Approved, Investigational
GuanadrelThe therapeutic efficacy of Guanadrel can be decreased when used in combination with Naproxen.Approved
GuanazodineThe therapeutic efficacy of Guanazodine can be decreased when used in combination with Naproxen.Experimental
GuanethidineThe therapeutic efficacy of Guanethidine can be decreased when used in combination with Naproxen.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Naproxen.Approved, Investigational
GuanoclorThe therapeutic efficacy of Guanoclor can be decreased when used in combination with Naproxen.Experimental
GuanoxabenzThe therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Naproxen.Experimental
GuanoxanThe therapeutic efficacy of Guanoxan can be decreased when used in combination with Naproxen.Experimental
HalcinonideThe risk or severity of gastrointestinal irritation can be increased when Halcinonide is combined with Naproxen.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of gastrointestinal irritation can be increased when Halometasone is combined with Naproxen.Experimental
HaloperidolThe therapeutic efficacy of Haloperidol can be increased when used in combination with Naproxen.Approved
HeparinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Heparin.Approved, Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Naproxen.Experimental
HydralazineNaproxen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Naproxen.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone aceponate is combined with Naproxen.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Naproxen.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Naproxen.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone probutate is combined with Naproxen.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone succinate is combined with Naproxen.Approved
Hydrocortisone valerateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone valerate is combined with Naproxen.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Naproxen.Approved, Investigational
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Hydrolyzed Cephalothin.Experimental
Hygromycin BThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Hygromycin B.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Naproxen is combined with Ibuproxam.Withdrawn
IcosapentThe risk or severity of adverse effects can be increased when Naproxen is combined with Icosapent.Approved, Nutraceutical
IdraparinuxThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Idraparinux.Investigational
IloprostThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Naproxen is combined with Imidazole salicylate.Experimental
ImipramineThe metabolism of Naproxen can be decreased when combined with Imipramine.Approved
Incadronic acidThe risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Incadronic acid.Approved, Investigational
IndalpineIndalpine may increase the antiplatelet activities of Naproxen.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Naproxen.Approved
IndenololNaproxen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Naproxen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Naproxen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Indoprofen.Withdrawn
IndoraminThe therapeutic efficacy of Indoramin can be decreased when used in combination with Naproxen.Withdrawn
IrbesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Naproxen.Approved, Investigational
IsepamicinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Isepamicin.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Naproxen is combined with Isoxicam.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Naproxen.Approved, Investigational
KanamycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Kebuzone.Experimental
KetanserinThe therapeutic efficacy of Ketanserin can be decreased when used in combination with Naproxen.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Naproxen.Approved
LabetalolNaproxen may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Naproxen.Approved, Investigational
LamotrigineThe serum concentration of Naproxen can be decreased when it is combined with Lamotrigine.Approved, Investigational
LandiololNaproxen may decrease the antihypertensive activities of Landiolol.Investigational
LatamoxefThe risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Naproxen.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Naproxen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Naproxen.Approved, Investigational
LepirudinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Naproxen.Approved, Investigational
LetaxabanThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Letaxaban.Investigational
LevobetaxololNaproxen may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololNaproxen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNaproxen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Naproxen.Approved, Investigational
LidocaineThe metabolism of Naproxen can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Naproxen.Approved, Investigational
LinsidomineThe therapeutic efficacy of Linsidomine can be decreased when used in combination with Naproxen.Experimental
LisinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Lisinopril.Approved, Investigational
Lithium cationNaproxen may decrease the excretion rate of Lithium cation which could result in a higher serum level.Experimental
LobeglitazoneThe metabolism of Naproxen can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Naproxen.Approved, Investigational
LomefloxacinNaproxen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Naproxen is combined with Lonazolac.Experimental
LoracarbefThe risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Naproxen.Investigational, Withdrawn
LornoxicamThe risk or severity of adverse effects can be increased when Naproxen is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Naproxen.Approved
LoteprednolThe risk or severity of gastrointestinal irritation can be increased when Loteprednol is combined with Naproxen.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Loxoprofen.Approved, Investigational
LumacaftorThe serum concentration of Naproxen can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Naproxen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Naproxen.Vet Approved
MacitentanThe therapeutic efficacy of Macitentan can be decreased when used in combination with Naproxen.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Naproxen is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Naproxen.Approved, Investigational
MannitolThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Naproxen.Approved, Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Naproxen.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of gastrointestinal irritation can be increased when Medrysone is combined with Naproxen.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Naproxen.Approved
MelagatranThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Melagatran.Experimental
MelengestrolThe risk or severity of gastrointestinal irritation can be increased when Melengestrol is combined with Naproxen.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Naproxen is combined with Meloxicam.Approved, Vet Approved
MepindololNaproxen may decrease the antihypertensive activities of Mepindolol.Experimental
MeprednisoneThe risk or severity of gastrointestinal irritation can be increased when Meprednisone is combined with Naproxen.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Naproxen is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Naproxen is combined with Metamizole.Approved, Investigational, Withdrawn
MethoserpidineThe therapeutic efficacy of Methoserpidine can be decreased when used in combination with Naproxen.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Naproxen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naproxen.Approved
Methyl salicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Naproxen.Approved, Vet Approved
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Naproxen.Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Naproxen.Approved, Vet Approved
MetipranololNaproxen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Naproxen.Approved
MetoprololNaproxen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetyrosineThe therapeutic efficacy of Metyrosine can be decreased when used in combination with Naproxen.Approved
MexiletineThe metabolism of Naproxen can be decreased when combined with Mexiletine.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Naproxen.Investigational, Withdrawn
MiconazoleThe metabolism of Naproxen can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Micronomicin.Experimental
MidostaurinThe metabolism of Naproxen can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Naproxen.Approved, Experimental
MifepristoneThe serum concentration of Naproxen can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Naproxen.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Naproxen.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Naproxen.Approved
MoexiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of gastrointestinal irritation can be increased when Mometasone is combined with Naproxen.Approved, Vet Approved
Mometasone furoateThe risk or severity of gastrointestinal irritation can be increased when Mometasone furoate is combined with Naproxen.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Naproxen is combined with Morniflumate.Approved
MoxifloxacinNaproxen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Naproxen.Approved, Investigational
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Naproxen.Experimental
NabiloneThe metabolism of Naproxen can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Naproxen.Approved
NadololNaproxen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Nafamostat.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Naproxen.Investigational
Nalidixic AcidNaproxen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NeamineThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Neamine.Experimental
NebivololNaproxen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Naproxen.Approved, Withdrawn
NelfinavirThe serum concentration of Naproxen can be decreased when it is combined with Nelfinavir.Approved
NemonoxacinNaproxen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Naproxen.Approved, Investigational
NetilmicinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Netilmicin.Approved, Investigational
NicardipineThe metabolism of Naproxen can be decreased when combined with Nicardipine.Approved, Investigational
NicorandilThe therapeutic efficacy of Nicorandil can be decreased when used in combination with Naproxen.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Naproxen is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Naproxen.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Naproxen.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Naproxen is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Naproxen.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Naproxen.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Naproxen.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Naproxen is combined with Nitroaspirin.Investigational
NitroprussideThe therapeutic efficacy of Nitroprusside can be decreased when used in combination with Naproxen.Approved, Investigational
NorfloxacinNaproxen may increase the neuroexcitatory activities of Norfloxacin.Approved
NS-398The risk or severity of adverse effects can be increased when Naproxen is combined with NS-398.Experimental
OfloxacinNaproxen may increase the neuroexcitatory activities of Ofloxacin.Approved
OlmesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Naproxen.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Naproxen is combined with Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Naproxen is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Omapatrilat.Investigational
OrbifloxacinNaproxen may increase the neuroexcitatory activities of Orbifloxacin.Vet Approved
OsimertinibThe serum concentration of Naproxen can be decreased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Naproxen is combined with Oxaprozin.Approved
OxcarbazepineThe serum concentration of Naproxen can be decreased when it is combined with Oxcarbazepine.Approved
Oxolinic acidNaproxen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololNaproxen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of gastrointestinal irritation can be increased when Paramethasone is combined with Naproxen.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Naproxen is combined with Parecoxib.Approved
PargylineThe therapeutic efficacy of Pargyline can be decreased when used in combination with Naproxen.Approved
ParnaparinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Naproxen.Approved, Investigational
PazufloxacinNaproxen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNaproxen may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Naproxen can be increased when it is combined with Peginterferon alfa-2b.Approved
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Naproxen.Approved, Investigational
PenbutololNaproxen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Pentamidine.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Naproxen.Approved
Pentosan PolysulfateThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Perindopril.Approved
PerindoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Perindoprilat.Experimental
PhenindioneNaproxen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Naproxen can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Naproxen.Approved
PhenprocoumonNaproxen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolamineThe therapeutic efficacy of Phentolamine can be decreased when used in combination with Naproxen.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Naproxen.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Naproxen can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PinacidilThe therapeutic efficacy of Pinacidil can be decreased when used in combination with Naproxen.Approved
PindololNaproxen may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidNaproxen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiperineThe metabolism of Naproxen can be decreased when combined with Piperine.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Naproxen.Approved
Piromidic acidNaproxen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Naproxen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Naproxen is combined with Pitolisant.Approved, Investigational
PlazomicinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Plazomicin.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Naproxen.Approved
Potassium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PractololNaproxen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateNaproxen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pranoprofen.Experimental, Investigational
PrasugrelThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Prasugrel.Approved
PrazosinThe therapeutic efficacy of Prazosin can be decreased when used in combination with Naproxen.Approved
PrednicarbateThe risk or severity of gastrointestinal irritation can be increased when Prednicarbate is combined with Naproxen.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Naproxen.Approved, Vet Approved
PrednisoneThe risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Naproxen.Approved, Vet Approved
PrednylideneThe risk or severity of gastrointestinal irritation can be increased when Prednylidene is combined with Naproxen.Experimental
PrimidoneThe serum concentration of Naproxen can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidProbenecid may decrease the excretion rate of Naproxen which could result in a higher serum level.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Naproxen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Naproxen is combined with Propacetamol.Approved, Investigational
PropafenoneNaproxen may decrease the antihypertensive activities of Propafenone.Approved
PropranololNaproxen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Naproxen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Naproxen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Naproxen.Vet Approved
Protein CThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Protein C.Approved
Protein S humanThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Protocatechualdehyde.Approved
PrulifloxacinNaproxen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PuromycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Puromycin.Experimental
QuinaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Quinaprilat.Experimental
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Naproxen.Approved
RamiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Ramipril.Approved
RamiprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Ramiprilat.Experimental
RemikirenThe therapeutic efficacy of Remikiren can be decreased when used in combination with Naproxen.Approved
RescinnamineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Rescinnamine.Approved
ReserpineThe therapeutic efficacy of Reserpine can be decreased when used in combination with Naproxen.Approved, Investigational
ReteplaseThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Reviparin.Approved, Investigational
RibostamycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Ribostamycin.Approved, Investigational
RifampicinThe serum concentration of Naproxen can be decreased when it is combined with Rifampicin.Approved
RifamycinThe metabolism of Naproxen can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Naproxen can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Naproxen can be increased when combined with Rifaximin.Approved, Investigational
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Naproxen.Approved, Investigational
RimexoloneThe risk or severity of gastrointestinal irritation can be increased when Rimexolone is combined with Naproxen.Approved
RiociguatThe therapeutic efficacy of Riociguat can be decreased when used in combination with Naproxen.Approved
RisedronateThe risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Risedronate.Approved, Investigational
RitanserinRitanserin may increase the antiplatelet activities of Naproxen.Investigational
RitonavirThe serum concentration of Naproxen can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Rivaroxaban.Approved
RobenacoxibThe risk or severity of adverse effects can be increased when Naproxen is combined with Robenacoxib.Experimental, Vet Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Naproxen.Approved, Investigational, Withdrawn
RopiniroleThe metabolism of Naproxen can be decreased when combined with Ropinirole.Approved, Investigational
RosoxacinNaproxen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinNaproxen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Naproxen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Naproxen is combined with Salsalate.Approved
SaprisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Naproxen.Experimental
SarafloxacinNaproxen may increase the neuroexcitatory activities of Sarafloxacin.Vet Approved, Withdrawn
SaralasinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Naproxen.Investigational
SaruplaseThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Saruplase.Experimental
SC-236The risk or severity of adverse effects can be increased when Naproxen is combined with SC-236.Experimental, Investigational
SecobarbitalThe metabolism of Naproxen can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe therapeutic efficacy of Selexipag can be decreased when used in combination with Naproxen.Approved
SertralineSertraline may increase the antiplatelet activities of Naproxen.Approved
SibutramineSibutramine may increase the antiplatelet activities of Naproxen.Approved, Illicit, Investigational, Withdrawn
SimeprevirThe metabolism of Naproxen can be decreased when combined with Simeprevir.Approved
SisomicinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Sisomicin.Investigational
SitafloxacinNaproxen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitaxentanThe therapeutic efficacy of Sitaxentan can be decreased when used in combination with Naproxen.Approved, Investigational, Withdrawn
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Naproxen.Approved
SotalolNaproxen may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinNaproxen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Streptokinase.Approved, Investigational
StreptomycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Streptomycin.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Naproxen is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Naproxen.Approved, Investigational
SulodexideThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Naproxen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Suxibuzone.Experimental
TacrolimusThe risk or severity of renal failure can be increased when Naproxen is combined with Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Naproxen.Approved
TalinololNaproxen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Naproxen is combined with Talniflumate.Approved
TasosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Naproxen.Approved
Technetium Tc-99m ciprofloxacinNaproxen may increase the neuroexcitatory activities of Technetium Tc-99m ciprofloxacin.Investigational
TelmisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Naproxen.Approved, Investigational
TemafloxacinNaproxen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Naproxen is combined with Tenidap.Experimental
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Naproxen.Experimental, Investigational
Tenofovir alafenamideThe serum concentration of Tenofovir alafenamide can be increased when it is combined with Naproxen.Approved
Tenofovir disoproxilNaproxen may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Naproxen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Naproxen is combined with Tepoxalin.Vet Approved
TerazosinThe therapeutic efficacy of Terazosin can be decreased when used in combination with Naproxen.Approved
TeriflunomideThe serum concentration of Naproxen can be decreased when it is combined with Teriflunomide.Approved
TertatololNaproxen may decrease the antihypertensive activities of Tertatolol.Experimental
Testosterone propionateThe serum concentration of Naproxen can be decreased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Naproxen.Investigational
TheophyllineThe metabolism of Naproxen can be decreased when combined with Theophylline.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Tiaprofenic acid.Approved
TicagrelorThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Ticagrelor.Approved
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Naproxen.Withdrawn
Tiludronic acidThe risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololNaproxen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Naproxen is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Tinzaparin.Approved
TioclomarolNaproxen may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Naproxen can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Naproxen.Approved, Withdrawn
TobramycinThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Tobramycin.Approved, Investigational
TocopherylquinoneThe therapeutic efficacy of Tocopherylquinone can be decreased when used in combination with Naproxen.Experimental, Investigational
TolazamideThe protein binding of Tolazamide can be decreased when combined with Naproxen.Approved, Investigational
TolazolineThe therapeutic efficacy of Tolazoline can be decreased when used in combination with Naproxen.Approved, Vet Approved
TolbutamideThe protein binding of Tolbutamide can be decreased when combined with Naproxen.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Naproxen is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Naproxen.Approved
TolonidineThe therapeutic efficacy of Tolonidine can be decreased when used in combination with Naproxen.Experimental
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Naproxen.Approved
TrandolaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Naproxen.Approved
TrazodoneTrazodone may increase the antiplatelet activities of Naproxen.Approved, Investigational
TreprostinilThe risk or severity of bleeding can be increased when Treprostinil is combined with Naproxen.Approved, Investigational
TriamcinoloneThe risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Naproxen.Approved, Vet Approved
TriamtereneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
TriflusalThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Triflusal.Approved, Investigational
TrilostaneThe risk or severity of gastrointestinal irritation can be increased when Trilostane is combined with Naproxen.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinThe therapeutic efficacy of Trimazosin can be decreased when used in combination with Naproxen.Experimental
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Naproxen.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Naproxen is combined with Trolamine salicylate.Approved
TrovafloxacinNaproxen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Troxerutin.Investigational
UlobetasolThe risk or severity of gastrointestinal irritation can be increased when Ulobetasol is combined with Naproxen.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Naproxen.Approved, Investigational
UrapidilThe therapeutic efficacy of Urapidil can be decreased when used in combination with Naproxen.Investigational
UrokinaseThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Naproxen.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Naproxen can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Naproxen.Approved, Investigational
VancomycinNaproxen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VemurafenibThe serum concentration of Naproxen can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Naproxen.Approved
VincamineThe therapeutic efficacy of Vincamine can be decreased when used in combination with Naproxen.Experimental
VorapaxarThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Vorapaxar.Approved
WarfarinNaproxen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Naproxen.Experimental
ZafirlukastThe metabolism of Naproxen can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Naproxen can be decreased when it is combined with Zidovudine.Approved
ZimelidineZimelidine may increase the antiplatelet activities of Naproxen.Withdrawn
ZofenoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Naproxen is combined with Zomepirac.Withdrawn
ZucapsaicinThe metabolism of Naproxen can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with a full glass of water.
  • Take with food.

References

Synthesis Reference
US4009197
General References
  1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006 Jun 3;332(7553):1302-8. [PubMed:16740558]
  2. Zhang J, Ding EL, Song Y: Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006 Oct 4;296(13):1619-32. Epub 2006 Sep 12. [PubMed:16968832]
External Links
Human Metabolome Database
HMDB0001923
KEGG Drug
D00118
KEGG Compound
C01517
PubChem Compound
156391
PubChem Substance
46505508
ChemSpider
137720
BindingDB
50339185
ChEBI
7476
ChEMBL
CHEMBL154
Therapeutic Targets Database
DAP000968
PharmGKB
PA450595
HET
NPS
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Naproxen
ATC Codes
M01AE52 — Naproxen and esomeprazoleM01AE02 — NaproxenM01AE56 — Naproxen and misoprostolM02AA12 — NaproxenG02CC02 — Naproxen
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
PDB Entries
2vdb / 3nt1 / 3r58 / 4fjp / 4jq1 / 4or0 / 4ot2 / 4po0 / 4zbr / 5dby
FDA label
Download (240 KB)
MSDS
Download (75.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentOssification, Heterotopic1
0CompletedBasic ScienceOsteoarthritis (OA)1
1Active Not RecruitingPreventionLynch Syndrome1
1CompletedNot AvailableGastroduodenal Erosions1
1CompletedNot AvailableHealthy Volunteers3
1CompletedNot AvailableHealthy Volunteers / Pharmacodynamic Interaction1
1CompletedNot AvailableMigraine Disorders / Migraines1
1CompletedNot AvailableOsteoarthritis Thumbs1
1CompletedNot AvailablePharmacokinetics1
1CompletedNot AvailableTherapeutic Equivalence1
1CompletedBasic ScienceAcute Gouty Arthritis1
1CompletedBasic ScienceArthritis2
1CompletedBasic ScienceBioequivalence / Healthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceJuvenile Idiopathic Arthritis (JIA)1
1CompletedBasic ScienceRenal Hemodynamics1
1CompletedDiagnosticOsteoarthritis (OA)1
1CompletedTreatmentBioavailability1
1CompletedTreatmentBioequivalency2
1CompletedTreatmentGastrointestinal Lesions1
1CompletedTreatmentHealthy Volunteers6
1CompletedTreatmentHematology / Pain1
1CompletedTreatmentKnee Osteoarthritis (Knee OA)2
1CompletedTreatmentOsteoarthritis (OA)1
1CompletedTreatmentPain4
1CompletedTreatmentPain, Acute1
1CompletedTreatmentPharmacokinetics1
1RecruitingOtherHealthy Volunteers1
1TerminatedBasic ScienceHealthy Volunteers1
1TerminatedBasic ScienceHealthy Volunteers / Pharmacodynamics of ASP7657 / Pharmacokinetics of ASP76571
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusTreatmentTMD1
1, 2CompletedPreventionGastric Ulcer (GU)1
1, 2CompletedTreatmentHealthy Volunteers1
1, 2CompletedTreatmentPain Management / Pulpitis dental1
2CompletedNot AvailableOsteoarthritis (OA)1
2CompletedPreventionAlzheimer's Disease (AD) / Cognitive Decline Due to Alzheimer Disease / Mild Cognitive Impairment Due to Alzheimer's Disease1
2CompletedPreventionErosion / Gastroduodenal Ulcerations1
2CompletedTreatmentAcute Gouty Arthritis / Moderate Renal Impairment1
2CompletedTreatmentBone Pain in Stage I - III Breast Cancer1
2CompletedTreatmentChronic Low Back Pain (CLBP)1
2CompletedTreatmentDental Pain1
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)3
2CompletedTreatmentKnee Osteoarthritis (Knee OA) / Lower Back Pain Chronic1
2CompletedTreatmentKnee Osteoarthritis (Knee OA) / Pain1
2CompletedTreatmentLow Back Pain (LBP)2
2CompletedTreatmentOsteoarthritis (OA)2
2CompletedTreatmentPain3
2CompletedTreatmentPharyngitis1
2CompletedTreatmentRheumatoid Arthritis1
2RecruitingPreventionPain, Neuropathic1
2TerminatedTreatmentKnee Osteoarthritis (Knee OA)1
2TerminatedTreatmentOsteoarthritis (OA)1
2TerminatedTreatmentPleural Effusion Malignant / Pleural Effusions1
2TerminatedTreatmentProstate Cancer / Prostatic Neoplasms1
2WithdrawnTreatmentPain, Acute1
2, 3CompletedTreatmentAdolescent Migraine / Migraines1
2, 3CompletedTreatmentAlzheimer's Disease (AD)1
2, 3CompletedTreatmentIdiopathic Intracranial Hypertension (IIH)1
2, 3CompletedTreatmentLow Back Pain (LBP)1
2, 3CompletedTreatmentOsteoarthritis (OA)1
2, 3WithdrawnTreatmentHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Immune Reconstitution Inflammatory Syndrome / Immune Reconstitution Syndrome / Tuberculosis1
3CompletedNot AvailablePain2
3CompletedPreventionAlzheimer's Disease (AD)1
3CompletedPreventionAnkylosing Spondylitis (AS) / Osteoarthritis (OA) / Rheumatoid Arthritis1
3CompletedSupportive CareMusculoskeletal Complications / Pain / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentAcute Gouty Arthritis1
3CompletedTreatmentAnkylosing Spondylitis (AS) / Spondyloarthritis, Axial1
3CompletedTreatmentArthritis / Cardiovascular Disease (CVD) / Cerebrovascular Disorders1
3CompletedTreatmentArthritis / Osteoarthritis (OA)1
3CompletedTreatmentDysmenorrhea1
3CompletedTreatmentGastric Ulcer (GU)3
3CompletedTreatmentKnee Osteoarthritis (Knee OA)1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis, Hip1
3CompletedTreatmentKnee / Osteoarthritis (OA)1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentMigraine Disorders1
3CompletedTreatmentMigraine Disorders / Migraine, Acute1
3CompletedTreatmentMigraine, Without Aura1
3CompletedTreatmentMigrainous Headache3
3CompletedTreatmentOsteoarthritis (OA)5
3CompletedTreatmentOsteoarthritis (OA) / Osteoarthritis, Hip1
3CompletedTreatmentOsteoarthritis (OA) / Peptic Ulcers1
3CompletedTreatmentPain1
3CompletedTreatmentPostoperative pain3
3CompletedTreatmentRelapsing Multiple Sclerosis (RMS) / Relapsing Remitting Multiple Sclerosis (RRMS)1
3CompletedTreatmentRheumatoid Arthritis, Juvenile3
3CompletedTreatmentToothache1
3RecruitingTreatmentAcute and Chronic Inflammation / Indigestion1
3RecruitingTreatmentHelicobacter Infections1
3RecruitingTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis, Hip1
3TerminatedTreatmentGastric Ulcer (GU)1
3Unknown StatusTreatmentBack Pain2
3WithdrawnTreatmentHeadaches / Migraines2
4Active Not RecruitingTreatmentAcute Gouty Arthritis1
4Active Not RecruitingTreatmentDysmenorrhea1
4CompletedNot AvailableGastroduodenal Ulcers1
4CompletedNot AvailableMigraines1
4CompletedPreventionMigraines2
4CompletedPreventionOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedPreventionPeptic Ulcers1
4CompletedTreatmentAcute Gouty Arthritis1
4CompletedTreatmentAcute Low Back Pain1
4CompletedTreatmentAnalgesics1
4CompletedTreatmentAnterior Cruciate Ligament Reconstruction1
4CompletedTreatmentBack Pain Lower Back1
4CompletedTreatmentChronic Migraine1
4CompletedTreatmentEpicondylitis of the Elbow1
4CompletedTreatmentEpicondylitis, Lateral Humeral / Lateral Epicondylitis1
4CompletedTreatmentHeadache Disorders, Primary / Headache, Tension-Type / Migraines1
4CompletedTreatmentHypermenorrhea2
4CompletedTreatmentJuvenile Idiopathic Arthritis (JIA)1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentLow Back Pain (LBP)1
4CompletedTreatmentMenstrual Migraines1
4CompletedTreatmentMigraine Disorders / Migraine With or Without Aura / Migraine, Acute / Migrainous Headache1
4CompletedTreatmentMigraines2
4CompletedTreatmentPost-Vaginal Delivery Perineal Pain1
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentRheumatoid Arthritis3
4CompletedTreatmentRheumatoid Arthritis, Juvenile1
4CompletedTreatmentSleep1
4CompletedTreatmentSub-acute Back Pain1
4Enrolling by InvitationTreatmentNonspecific Pain Post Traumatic Injury1
4RecruitingBasic SciencePoor Metabolizer Due to Cytochrome P450 CYP2C19 Variant / Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant1
4RecruitingPreventionAnaesthesia therapy / Hip Fractures1
4RecruitingTreatmentChronic Low Back Pain (CLBP)2
4RecruitingTreatmentLigament Injury1
4RecruitingTreatmentOsteoarthritis (OA)1
4RecruitingTreatmentSciatica1
4TerminatedPreventionPost-Traumatic Headaches1
4TerminatedTreatmentHealthy Volunteers1
4Unknown StatusTreatmentPostoperative Laminectomy Pain / Postoperative pain1
4Unknown StatusTreatmentPostoperative pain1
4WithdrawnPreventionOssification, Heterotopic1
4WithdrawnSupportive CareClosed Fracture of Ankle1
Not AvailableCompletedNot AvailableMigraine Disorders3
Not AvailableCompletedNot AvailableMigraines1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedPreventionContraception / Haemorrhage1
Not AvailableCompletedPreventionTooth Bleaching / Toothache1
Not AvailableCompletedSupportive CareContraception1
Not AvailableCompletedTreatmentContraception / Pain1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentOsteoarthritis (OA)4
Not AvailableCompletedTreatmentRenal Stones1
Not AvailableRecruitingBasic ScienceAchilles Tendinopathy / Inflammatory Reaction / Tendon Injuries1
Not AvailableRecruitingTreatmentGeneral Surgery / Pain / Rib Fractures / Traumas1
Not AvailableRecruitingTreatmentHip Pain Chronic1
Not AvailableRecruitingTreatmentIUD Insertion Complication1
Not AvailableRecruitingTreatmentMigraines1
Not AvailableUnknown StatusNot AvailableCognitive Impairments / Migrainous Headache1
Not AvailableUnknown StatusTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableUnknown StatusTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableUnknown StatusTreatmentMigraine With Aura1
Not AvailableUnknown StatusTreatmentPain1
Not AvailableWithdrawnSupportive CareToothache1

Pharmacoeconomics

Manufacturers
  • Roche palo alto llc
  • Roxane laboratories inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Amneal pharmaceuticals ny llc
  • Baxter healthcare corp anesthesia and critical care
  • Dava pharmaceuticals inc
  • Glenmark generics ltd
  • Hamilton pharmaceuticals ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Perrigo r and d co
  • Purepac pharmaceutical co
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Westward pharmaceutical corp
  • Zydus pharmaceuticals usa inc
  • Banner pharmacaps inc
  • Stat trade inc
  • Watson laboratories inc florida
  • Bayer healthcare llc
  • Able laboratories inc
  • Contract pharmacal corp
  • Dr reddys laboratories inc
  • Dr reddys laboratories ltd
  • Hikma pharmaceuticals
  • L perrigo co
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Altura Pharmaceuticals Inc.
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotheca Inc.
  • Apothecary Shop Wholesale
  • A-S Medication Solutions LLC
  • AstraZeneca Inc.
  • Atlantic Biologicals Corporation
  • Avkare Incorporated
  • Bayer Healthcare
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • Cardinal Health
  • Chain Drug
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • CVS Pharmacy
  • DAVA Pharmaceuticals
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Elan Pharmaceuticals Inc.
  • Ethex Corp.
  • F Hoffmann-La Roche Ltd.
  • Glenmark Generics Ltd.
  • Golden State Medical Supply Inc.
  • Group Health Cooperative
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hikma Pharmaceuticals
  • Innovative Manufacturing and Distribution Services Inc.
  • Innoviant Pharmacy Inc.
  • International Ethical Labs Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Legacy Pharmaceuticals Packaging LLC
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Medique Products
  • Medisca Inc.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patheon Inc.
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Pharmpak Inc.
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Quality Pharmaceuticals Services Inc.
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Talbert Medical Management Corp.
  • Teva Pharmaceutical Industries Ltd.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Victory Pharma
  • Walgreen Co.
  • Watson Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral200 mg/1
TabletOral275 mg/1
TabletOral125 mg
CapsuleOral220 mg/1
TabletOral200 mg/1
KitTopical
Tablet, film coatedOral220 mg/1
CapsuleOral200 mg
KitOral
Tablet, extended releaseOral375 mg
Tablet, extended releaseOral500 mg
Tablet, film coated, extended releaseOral500 mg/1
Tablet, film coated, extended releaseOral750 mg/1
SuspensionOral125 mg/5mL
TabletOral250 mg/1
TabletOral375 mg/1
SuspensionOral25 mg
Tablet, extended releaseOral750 mg
TabletOral220 mg
TabletOral500 mg/500mg
Tablet, delayed releaseOral375 mg/1
Tablet, delayed releaseOral500 mg/1
CapsuleOral
TabletOral500 mg/1
Kit
CapsuleOral220 mg
Capsule, liquid filledOral220 mg/1
TabletOral200 1/1
TabletOral275 mg
TabletOral550 mg/1
Tablet, coatedOral220 mg/1
Tablet, film coatedOral275 mg/1
Tablet, film coatedOral550 mg/1
Tablet, film coated, extended releaseOral220 mg/1
Tablet, film coated, extended releaseOral375 mg/1
TabletOral220 mg/200mg
TabletOral220 mg/1
SuspensionOral125 mg
SuppositoryRectal500 mg
Tablet, film coated, extended releaseOral
TabletOral250 mg
TabletOral375 mg
TabletOral500 mg
Tablet, delayed releaseOral250 mg
Tablet, delayed releaseOral375 mg
Tablet, delayed releaseOral500 mg
TabletOral550 mg
Kit
Tablet, film coatedOral
Tablet, delayed releaseOral
Prices
Unit descriptionCostUnit
Naproxen 125 mg/5ml Suspension 500ml Bottle51.5USD bottle
Naprelan 750 mg 24 Hour tablet8.87USD tablet
Naprelan cr 500 mg tablet8.5USD tablet
Naprelan cr 750 mg tablet8.02USD tablet
Naprelan cr dosecrd 500-750 mg5.98USD each
Naprelan 375 mg 24 Hour tablet4.34USD tablet
Anaprox ds 550 mg tablet3.66USD tablet
Naprelan 500 mg 24 Hour tablet3.63USD tablet
Naprelan cr 375 mg tablet3.52USD tablet
Naproxen sodium powder2.63USD g
Anaprox 275 mg tablet2.52USD tablet
Naprosyn 500 mg tablet2.42USD tablet
Naproxen powder2.26USD g
Naprosyn 500 mg tablet ec2.19USD tablet
Naprosyn 375 mg tablet1.93USD tablet
Ec-naprosyn 375 mg tablet ec1.79USD tablet
Naprosyn 250 mg tablet1.47USD tablet
Naprosyn Sr 750 mg Sustained-Release Tablet1.43USD tablet
Anaprox Ds 550 mg Tablet1.33USD tablet
Naproxen 500 mg tablet1.32USD tablet
Naproxen sodium 550 mg tablet1.32USD tablet
Naproxen DR 500 mg Enteric Coated Tabs1.3USD tab
Naproxen DR 375 mg Enteric Coated Tabs1.11USD tab
Naprosyn E 500 mg Enteric-Coated Tablet1.09USD tablet
Naproxen 375 mg tablet1.08USD tablet
Apo-Naproxen Sr 750 mg Sustained-Release Tablet1.05USD tablet
Pms-Naproxen 500 mg Suppository0.87USD suppository
Naproxen sodium 275 mg tablet0.86USD tablet
Naproxen 250 mg tablet0.79USD tablet
Apo-Napro-Na Ds 550 mg Tablet0.7USD tablet
Novo-Naprox Sodium Ds 550 mg Tablet0.7USD tablet
Anaprox 275 mg Tablet0.69USD tablet
Apo-Naproxen Ec 500 mg Enteric-Coated Tablet0.61USD tablet
Mylan-Naproxen Ec 500 mg Enteric-Coated Tablet0.61USD tablet
Novo-Naprox Ec 500 mg Enteric-Coated Tablet0.61USD tablet
Pms-Naproxen Ec 500 mg Enteric-Coated Tablet0.61USD tablet
Naprosyn E 375 mg Enteric-Coated Tablet0.6USD tablet
Naprosyn E 250 mg Enteric-Coated Tablet0.46USD tablet
Apo-Napro-Na 275 mg Tablet0.36USD tablet
Novo-Naprox Sodium 275 mg Tablet0.36USD tablet
Apo-Naproxen Ec 375 mg Enteric-Coated Tablet0.34USD tablet
Mylan-Naproxen Ec 375 mg Enteric-Coated Tablet0.34USD tablet
Novo-Naprox Ec 375 mg Enteric-Coated Tablet0.34USD tablet
Pms-Naproxen Ec 375 mg Enteric-Coated Tablet0.34USD tablet
Apo-Naproxen Ec 250 mg Enteric-Coated Tablet0.26USD tablet
Novo-Naprox Ec 250 mg Enteric-Coated Tablet0.26USD tablet
Apo-Naproxen 500 mg Tablet0.22USD tablet
Novo-Naprox 500 mg Tablet0.22USD tablet
Nu-Naprox 500 mg Tablet0.22USD tablet
Aleve 220 mg gelcap0.19USD capsule
Naprosyn 125 mg/5ml Suspension0.18USD ml
Mediproxen tablet0.17USD tablet
Apo-Naproxen 375 mg Tablet0.15USD tablet
Naproxen sodium 220 mg tablet0.15USD tablet
Novo-Naprox 375 mg Tablet0.15USD tablet
Nu-Naprox 375 mg Tablet0.15USD tablet
CVS Pharmacy all day pain rlf 220 mg tb0.12USD tablet
Wal-proxen 220 mg tablet0.12USD tablet
Apo-Naproxen 250 mg Tablet0.11USD tablet
Novo-Naprox 250 mg Tablet0.11USD tablet
Nu-Naprox 250 mg Tablet0.11USD tablet
All day pain rlf 220 mg caplet0.1USD caplet
Aleve 220 mg caplet0.09USD caplet
Aleve 220 mg tablet0.09USD tablet
Wal-proxen 220 mg caplet0.09USD tablet
Apo-Naproxen 125 mg Tablet0.08USD tablet
All day pain relief 220 mg tablet0.07USD tablet
Naprosyn 25 mg/ml Suspension0.07USD ml
Naproxen sodium 220 mg caplet0.06USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5637320No1994-06-102014-06-10Us
CA2034096No2002-03-262011-01-14Canada
US6060499Yes1998-02-142018-02-14Us
US7332183Yes2006-04-022026-04-02Us
US6586458Yes1998-02-142018-02-14Us
US5872145Yes1998-02-142018-02-14Us
US8022095Yes1998-02-142018-02-14Us
US5900424Yes1996-11-042016-11-04Us
US6369085Yes1998-11-252018-11-25Us
US7411070Yes1998-11-252018-11-25Us
US8852636No2002-05-312022-05-31Us
US8858996No2002-05-312022-05-31Us
US6926907No2003-02-282023-02-28Us
US7745466No1998-10-132018-10-13Us
US9161920No2002-05-312022-05-31Us
US9198888No2002-05-312022-05-31Us
US8945621No2011-10-172031-10-17Us
US8557285No2002-05-312022-05-31Us
US9220698No2011-03-102031-03-10Us
US5714504Yes1995-08-032015-08-03Us
US9345695No2002-05-312022-05-31Us
US9393208No2009-09-032029-09-03Us
US9707181No2002-05-312022-05-31Us
US9693978No2006-03-032026-03-03Us
US9693979No2006-03-032026-03-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)153 °CPhysProp
water solubility15.9 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.18HANSCH,C ET AL. (1995)
logS-4.16ADME Research, USCD
Caco2 permeability-4.83ADME Research, USCD
pKa4.15SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0511 mg/mLALOGPS
logP3.29ALOGPS
logP2.99ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)4.19ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity64.85 m3·mol-1ChemAxon
Polarizability24.81 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.6881
Caco-2 permeable+0.9091
P-glycoprotein substrateNon-substrate0.586
P-glycoprotein inhibitor INon-inhibitor0.8747
P-glycoprotein inhibitor IINon-inhibitor0.8396
Renal organic cation transporterNon-inhibitor0.8615
CYP450 2C9 substrateNon-substrate0.7548
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5715
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9521
CYP450 2C19 inhibitorNon-inhibitor0.9447
CYP450 3A4 inhibitorNon-inhibitor0.8905
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8598
Ames testAMES toxic0.5184
CarcinogenicityNon-carcinogens0.8685
BiodegradationNot ready biodegradable0.7809
Rat acute toxicity2.4579 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9588
hERG inhibition (predictor II)Non-inhibitor0.9144
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.95 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-001i-0190000000-64cc22cce1238357760e
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-0f79-0900000000-17f4e93fda31d93027a1
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-0fr6-0900000000-4dd08568cff27d62d867
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-000i-0910000000-149b16cac2d80de64d8a
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-00di-0900000000-e7dfead967f29853140d
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-01b9-0900000000-f5f45cee188a08ef62b1
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-014i-0900000000-6c076658da1c69f1b909
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-014i-0900000000-2e1269f26d5b927bca33
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-000i-0900000000-68cd0c5a3fcc15470c14
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00di-0900000000-64e5ecb5632e32f89b2d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-0910000000-149b16cac2d80de64d8a
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00di-0900000000-e7dfead967f29853140d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-01b9-0900000000-f5f45cee188a08ef62b1
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0900000000-6c076658da1c69f1b909
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0900000000-2e1269f26d5b927bca33
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000i-0900000000-b913db958cba90673250
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Anisoles / Alkyl aryl ethers / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Naphthalene / Anisole / Alkyl aryl ether / Monocarboxylic acid or derivatives / Ether / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
monocarboxylic acid, methoxynaphthalene (CHEBI:7476)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. James MJ, Cook-Johnson RJ, Cleland LG: Selective COX-2 inhibitors, eicosanoid synthesis and clinical outcomes: a case study of system failure. Lipids. 2007 Sep;42(9):779-85. Epub 2007 Jun 2. [PubMed:17541796]
Kind
Protein
Organism
Peptostreptococcus magnus
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Binds serum albumin.
Gene Name
pab
Uniprot ID
Q51911
Uniprot Name
Peptostreptococcal albumin-binding protein
Molecular Weight
43057.45 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Albertini R, Aimbire F, Villaverde AB, Silva JA Jr, Costa MS: COX-2 mRNA expression decreases in the subplantar muscle of rat paw subjected to carrageenan-induced inflammation after low level laser therapy. Inflamm Res. 2007 Jun;56(6):228-9. [PubMed:17607546]
  2. Dhir A, Naidu PS, Kulkarni SK: Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure. 2007 Dec;16(8):691-7. Epub 2007 Jul 2. [PubMed:17604186]
  3. Kumar P, Padi SS, Naidu PS, Kumar A: Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol. 2007 Jun;21(3):297-306. [PubMed:17521299]
  4. White WB: Cardiovascular effects of the selective cyclooxygenase-2 inhibitors. Subcell Biochem. 2007;42:145-58. [PubMed:17612049]
  5. Hassan-Alin M, Naesdal J, Nilsson-Pieschl C, Langstrom G, Andersson T: Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Clin Drug Investig. 2005;25(11):731-40. [PubMed:17532719]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Banerjee T, Singh SK, Kishore N: Binding of naproxen and amitriptyline to bovine serum albumin: biophysical aspects. J Phys Chem B. 2006 Nov 30;110(47):24147-56. [PubMed:17125386]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  2. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:45